ATE161192T1 - Verfahren zur behandlung einer durch lfa-1 vermittelten störung - Google Patents

Verfahren zur behandlung einer durch lfa-1 vermittelten störung

Info

Publication number
ATE161192T1
ATE161192T1 AT93920241T AT93920241T ATE161192T1 AT E161192 T1 ATE161192 T1 AT E161192T1 AT 93920241 T AT93920241 T AT 93920241T AT 93920241 T AT93920241 T AT 93920241T AT E161192 T1 ATE161192 T1 AT E161192T1
Authority
AT
Austria
Prior art keywords
lfa
treating
antibody
disorder mediated
effective amount
Prior art date
Application number
AT93920241T
Other languages
English (en)
Inventor
Paula M Jardieu
Bruce Montgomery
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE161192T1 publication Critical patent/ATE161192T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT93920241T 1992-08-21 1993-08-20 Verfahren zur behandlung einer durch lfa-1 vermittelten störung ATE161192T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93326992A 1992-08-21 1992-08-21

Publications (1)

Publication Number Publication Date
ATE161192T1 true ATE161192T1 (de) 1998-01-15

Family

ID=25463656

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920241T ATE161192T1 (de) 1992-08-21 1993-08-20 Verfahren zur behandlung einer durch lfa-1 vermittelten störung

Country Status (14)

Country Link
US (4) US5622700A (de)
EP (1) EP0656789B1 (de)
JP (1) JPH08500826A (de)
AT (1) ATE161192T1 (de)
AU (1) AU687755B2 (de)
CA (1) CA2140933A1 (de)
DE (1) DE69315847T2 (de)
DK (1) DK0656789T3 (de)
ES (1) ES2112431T3 (de)
GR (1) GR3026344T3 (de)
IL (1) IL106756A (de)
MX (1) MX9305070A (de)
WO (1) WO1994004188A1 (de)
ZA (1) ZA936128B (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
AU6256796A (en) * 1995-06-06 1996-12-24 D. Allen Allen Method for treating molluscum contagiosum resulting from hiv infection
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
WO1997036602A1 (en) * 1996-03-29 1997-10-09 Universite Laval Method of restoring a functional protein in a tissue by cell transplantation
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
FR2763072B1 (fr) * 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
SK156099A3 (en) * 1997-05-17 2000-06-12 Biogen Inc Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
AU1727500A (en) * 1998-11-17 2000-06-05 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
DK1163003T3 (da) * 1999-03-19 2009-11-30 Genentech Inc Behandling af LFA-1 associerede lidelser med ögende doser af LFA-1-antagonist
ATE403437T1 (de) * 1999-12-14 2008-08-15 Genentech Inc Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US6663863B2 (en) 2000-03-17 2003-12-16 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis
EP1315812B1 (de) 2000-09-01 2009-11-11 The Center for Blood Research, INC. Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
EP2270185A3 (de) 2001-06-22 2012-04-04 Pioneer Hi-Bred International, Inc. Defensinpolynucleotide und Verfahren zu ihrer Verwendung
DK1472275T3 (da) 2002-02-05 2009-04-14 Genentech Inc Proteinoprensning
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
CN102993306B (zh) 2003-02-01 2015-01-28 唐纳士公司 高亲和力抗人类IgE抗体
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
EP3722309A1 (de) * 2003-07-28 2020-10-14 Genentech, Inc. Verringerung des protein-a-auslaugens während einer affinitätschromatografie
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
EP2264191A1 (de) 2003-11-21 2010-12-22 ANP Technologies, Inc. Asymmetrisch verzweigte Polymerkonjugate und Mikroarray-Tests
EP1735000A2 (de) * 2004-04-16 2006-12-27 Genentech, Inc. Verfahren zur verstärkung des b-zellabbaus
US7396530B2 (en) * 2004-06-09 2008-07-08 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
WO2006028956A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102004059357B8 (de) * 2004-12-03 2009-12-03 Universität Leipzig Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung
AU2006242303A1 (en) 2005-05-02 2006-11-09 Anp Technologies, Inc. Polymer conjugate enhanced bioassays
WO2006125119A1 (en) 2005-05-17 2006-11-23 Sarcode Corporation Compositions and methods for treatment of eye disorders
US20080279848A1 (en) * 2006-03-16 2008-11-13 Genentech, Inc. Methods of treating lupus using CD4 antibodies
EP2001510A4 (de) * 2006-03-16 2010-06-09 Genentech Inc Verfahren zur behandlung von lupus mit cd4-antikörpern
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
ES2612383T3 (es) 2006-07-19 2017-05-16 The Trustees Of The University Of Pennsylvania WSX-1/IL-27 como una diana para respuestas antiinflamatorias
TWI472535B (zh) 2006-11-02 2015-02-11 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US20100267933A1 (en) * 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
US7947813B2 (en) 2007-01-22 2011-05-24 Genentech, Inc. Polyelectrolyte precipitation and purification of proteins
EP1995309A1 (de) * 2007-05-21 2008-11-26 Vivalis Rekombinante Proteinproduktion in EBx -Vogelzellen
SI3597659T1 (sl) 2007-07-09 2023-04-28 Genentech, Inc. Preprečevanje redukcije disulfidne vezi med rekombinantno proizvodnjo polipeptidov
EP2209371B1 (de) * 2007-10-19 2017-01-04 SARcode Bioscience Inc. Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
ES2666170T3 (es) 2007-10-30 2018-05-03 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
US20090258070A1 (en) * 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009151514A1 (en) * 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
AR077718A1 (es) * 2008-07-15 2011-09-21 Genentech Inc Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
KR102196883B1 (ko) 2008-08-14 2020-12-30 제넨테크, 인크. 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
EP2684570A1 (de) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Zusammensetzungen und Verfahren zur Prävention des oxidativen Abbaus von Proteinen
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
CN102257122B (zh) 2008-12-16 2015-07-29 Emd密理博公司 搅拌槽反应器及方法
US20110020327A1 (en) * 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
ES2547712T3 (es) 2009-02-27 2015-10-08 Genentech, Inc. Métodos y composiciones para el marcado de proteínas
EP3431588A1 (de) 2009-08-11 2019-01-23 F. Hoffmann-La Roche AG Herstellung von proteinen in glutamin-freien zellkulturmedien
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2531592A1 (de) 2010-02-04 2012-12-12 Vivalis Fed-batch-verfahren mit konzentriertem zellkulturmedium zur effizienten produktion von biologischen wirkstoffen bei eb66-zellen
JP5937059B2 (ja) 2010-03-22 2016-06-22 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
MX2012011112A (es) 2010-03-31 2012-10-15 Boehringer Ingelheim Int Anticuerpos anti-cd40.
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
CN102985437B (zh) 2010-05-28 2016-05-25 弗·哈夫曼-拉罗切有限公司 通过下调ldh和pdhk表达降低乳酸水平和增加多肽生产
MX339666B (es) 2010-06-24 2016-06-03 Genentech Inc * Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
CA2807785A1 (en) 2010-08-23 2012-03-01 Pioneer Hi-Bred International, Inc. Novel defensin variants and methods of use
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EA030436B1 (ru) 2010-11-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх АНТИТЕЛА К IL-23p19 ИЛИ ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ, ИХ ПРИМЕНЕНИЕ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЭТИ АНТИТЕЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ВЫДЕЛЕННЫЕ ПОЛИНУКЛЕОТИДЫ, ЭКСПРЕССИОННЫЕ ВЕКТОРЫ И КЛЕТКИ ДЛЯ ПОЛУЧЕНИЯ АНТИТЕЛ
CN103429267B (zh) 2011-01-09 2016-05-04 Anp科技公司 疏水分子诱导的支化聚合物集合体及其用途
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
EP3722304A1 (de) 2011-07-08 2020-10-14 EMD Millipore Corporation Verbesserte tiefenfilter für biotechnologische einwegverfahren
PL2780373T3 (pl) 2011-11-16 2020-03-31 Boehringer Ingelheim International Gmbh Przeciwciała anty il-36r
SG11201403437TA (en) 2011-12-22 2014-07-30 Genentech Inc Ion exchange membrane chromatography
US20140080180A1 (en) 2012-03-27 2014-03-20 Genentech, Inc. Harvest operations for recombinant proteins
EP3326649B1 (de) 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anti-il-23p19-antikörper
US20130309226A1 (en) 2012-05-18 2013-11-21 Genentech, Inc. High-concentration monoclonal antibody formulations
CN110922393A (zh) 2012-07-25 2020-03-27 诺华股份有限公司 Lfa-1抑制剂及其多晶型物
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
WO2014123791A1 (en) 2013-02-05 2014-08-14 Anp Technologies, Inc. Nanoparticles containing a taxane and their use
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
EP4285988A3 (de) 2013-03-27 2024-03-06 Cedars-Sinai Medical Center Behandlung von fibrose durch tl1a-hemmung
EP4105236A1 (de) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antikörper zur behandlung von entzündlichen darmerkrankungen
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
JP6511459B2 (ja) 2014-01-31 2019-05-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な抗ｂａｆｆ抗体
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
RU2714759C2 (ru) 2014-07-09 2020-02-19 Дженентек, Инк. Корректировка ph для улучшения размораживания банков клеток
EP3708679A1 (de) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH In der behandlung von il-23a-assoziierten erkrankungen nützlicher biomarker
US20170058038A1 (en) 2015-09-01 2017-03-02 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of lupus nephritis
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
KR20220153109A (ko) 2016-03-17 2022-11-17 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
US10941406B2 (en) 2016-03-29 2021-03-09 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
US20180273627A1 (en) 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
KR20210027436A (ko) 2018-06-29 2021-03-10 베링거 인겔하임 인터내셔날 게엠베하 자가면역 질환을 치료하는데 사용하기 위한 항-cd40 항체
EP3818078B1 (de) 2018-07-03 2024-02-28 Bristol-Myers Squibb Company Verfahren zur herstellung rekombinanter proteine
EP3864127A1 (de) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Verfahren zur membrangasübertragung in einer hochdichten bioreaktorkultur
CA3132917A1 (en) 2019-03-08 2020-09-17 Boehringer Ingelheim International Gmbh Anti-il-36r antibody formulations
AU2020254582A1 (en) 2019-04-01 2021-09-30 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
TW202104254A (zh) 2019-04-12 2021-02-01 美商格爾托公司 重組彈性蛋白及其生產
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
CR20220489A (es) 2020-03-24 2022-10-31 Genentech Inc Agentes de fijación a tie2 y métodos de uso.
TW202229344A (zh) 2020-09-21 2022-08-01 德商百靈佳殷格翰國際股份有限公司 抗-cd40抗體用於治療發炎病況之用途
JP2023542924A (ja) 2020-09-22 2023-10-12 ブリストル－マイヤーズ スクイブ カンパニー 治療タンパク質を生産するための方法
WO2022170008A2 (en) 2021-02-05 2022-08-11 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292636A (en) * 1986-03-31 1994-03-08 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
US5762933A (en) * 1987-01-05 1998-06-09 Institut National De La Sante Et De La Recherche Medicale Method for preventing and treating graft failure in a human patient using a monoclonal antibody specific for leucocyte functional antigen LFA-1
WO1988006592A1 (en) * 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Cloning of lfa-1
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) * 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2011633C (en) * 1989-03-09 2007-05-15 Timothy A. Springer Intercellular adhesion molecule - 2 and its binding ligands
JPH04505009A (ja) * 1989-03-09 1992-09-03 ダナ・ファーバー・キャンサー・インスティチュート クローニングｌｆａ―１
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
ATE143376T1 (de) * 1989-06-02 1996-10-15 Univ Johns Hopkins Med Gegen die beta-kette des leukozyten-adhäsions- rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
AU8631991A (en) * 1990-08-27 1992-03-17 Cetus Corporation Cd18 peptide medicaments for the treatment of disease
JPH06501931A (ja) * 1990-08-31 1994-03-03 ベーリンガー・インゲルハイム・ファーマシュウティカルズ・インコーポレイテッド 抗接着性抗体を用いるエンドトキシンショックの治療法
EP0590058B1 (de) * 1991-06-14 2003-11-26 Genentech, Inc. Humanisierter Heregulin Antikörper
EP0610298A1 (de) * 1991-10-01 1994-08-17 The General Hospital Corporation Verhinderung der Abstossung eines Wirt-Transplantats durch Verwendung von gegen Adhäsionsmolekülen gebildeten Antikörpern
US5854070A (en) * 1992-07-16 1998-12-29 Icos Corporation Murine and humanizer 23F2G antibodies and cell lines expressing said antibodies
CA2119128C (en) * 1992-07-16 2000-05-30 Lynn M. Rose Alleviation of symptoms associated with inflammatory disease states
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder

Also Published As

Publication number Publication date
ZA936128B (en) 1995-02-20
DK0656789T3 (da) 1998-08-24
CA2140933A1 (en) 1994-02-22
JPH08500826A (ja) 1996-01-30
EP0656789A1 (de) 1995-06-14
GR3026344T3 (en) 1998-06-30
US5622700A (en) 1997-04-22
US20050281817A1 (en) 2005-12-22
ES2112431T3 (es) 1998-04-01
MX9305070A (es) 1994-04-29
DE69315847D1 (de) 1998-01-29
IL106756A (en) 2006-07-05
US20040120960A1 (en) 2004-06-24
EP0656789B1 (de) 1997-12-17
WO1994004188A1 (en) 1994-03-03
US20020197248A1 (en) 2002-12-26
DE69315847T2 (de) 1998-06-25
AU5083693A (en) 1994-03-15
AU687755B2 (en) 1998-03-05
IL106756A0 (en) 1993-12-08

Similar Documents

Publication Publication Date Title
ATE161192T1 (de) Verfahren zur behandlung einer durch lfa-1 vermittelten störung
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
DE69736712D1 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
DE69318835T2 (de) Behandlung einer refluxstörung durch injektion von mikropartikeln
DE69334035D1 (de) Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden
DE69433079D1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
DE69229275D1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
ES8203605A1 (es) Un procedimiento de preparacion de una composicion farmaceu-tica de un esteroide
ATE196849T1 (de) Verfahren zur behandlung von multiplesklerose
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DK0863760T3 (da) Anvendelse af forbindelser med antimineralcorticoid virkning over for narkotikafvænning
ATE73350T1 (de) Verfahren zur tierischen wachstumsfoerderung.
NZ337073A (en) use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
HK1014498A1 (en) Bpi-protein-products for depressed reticuloendothelial system function.
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
ATE308994T1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
MY104521A (en) Treatment of depression.
ATE100331T1 (de) Verfahren zur behandlung von septischem schock.
ATE202935T1 (de) Verfahren zur behandlung von haarausfall
ATE17007T1 (de) Neue o-alkyl-o-carbamoyl-glycero-phosphocholine und verfahren zu ihrer herstellung.
DE69218200D1 (de) Behandlung von leberkrebs
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee